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THE TRUTH BEHIND ASPARTAME: AN EXAMINATION OF THE ADVERSE  
 
HEALTH EFFECTS ASSOCIATED WITH ITS CONSUMPTION 
NAVEED MAJD  
ABSTRACT 
 Aspartame (APM) is one of the most widely used artificial sweeteners in the 
world today. It is present in over 6,000 different products and is consumed by millions of 
people on a daily basis. Since its approval by the United States Food and Drug 
Administration (FDA) in 1981, APM has made its way into the normal diets of many 
people. The negligible caloric content of APM has led to increases in its use by not only 
diabetics but also a large number of health conscious people. Since the introduction of 
APM into the food industry, there has been great debate and controversy over the safety 
of its use. Numerous animal and human studies have shown that APM use is fully 
harmless and not linked to any negative health effects in humans. On the other hand, 
other studies have found APM consumption to be associated with a variety of alarming 
health consequences. These include various types of cancers, genotoxicity, diabetes, 
metabolic syndrome, oxidative stress, neurochemical imbalances, and shifts in gut 
microbial balance. Many APM users believe that through consuming products that 
contain APM, they are reducing their risk of some of these conditions while in reality it is 
possible that quite the opposite is happening. APM use may not be as safe as the public 
generally assumes. The circumstances that surrounded the FDA’s approval of APM and 
the body of evidence that exists pertaining to APM toxicity raise many questions. An 
extensive look into the literature has revealed that there are enough reasons to doubt the 
	  	   v 
complete safety of APM. It is important for the public to be made aware of these findings 
in order to make well-informed decisions and more importantly, to best protect their 
health.  
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INTRODUCTION 	  	  	  
Obesity rates in the United States have been increasing significantly every year 
over the past several decades and this trend is not expected to slow down anytime soon. 
Currently over one-third of Americans are obese and over two-thirds are either 
overweight or obese. By the year 2030, the prevalence of obesity in the United States is 
projected to reach approximately 50% (Levi et al., 2012). In efforts to lose weight and 
reduce their risk of conditions such as diabetes, cancer, heart disease, and hypertension, 
millions of Americans and people around the world have incorporated low-calorie foods 
and beverages into their normal lifestyle. This has resulted in a huge expansion of this 
sector of the food industry and the production of a large number of low-calorie products. 
With sugar being a main source of calories, artificial sweeteners have made their way 
into these products and gained a lot of popularity in the public due to their negligible 
caloric content. The first artificial sweetener approved for human consumption was 
saccharin. It was discovered in 1879 and is still used in a variety of products (Saccharin, 
2015). Since then many other artificial sweeteners have found their way into the market, 
such as neotame, sucralose, and acesulfame potassium. One of the most widely used 
artificial sweeteners today is aspartame (APM), which has been produced under the brand 
names of NutraSweet and Equal.  
Aspartame (methyl L-α-aspartyl-L-phenylalanine) is an artificial sweetener that is 
currently being used in over 6,000 products (Aspartame Information Center, 2015). Some 
of these products include diet beverages, yogurts, cereals, candies, desserts, and tabletop 
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sweeteners. It is even found in a variety of pharmaceutical products such as Zofran, 
children’s Benadryl, and sugar-free cough drops. APM has a caloric value of 4 
kilocalories/gram; however, since it is 200 times the sweetness of sucrose (table sugar),  
small amounts are used in products and it is considered a calorie-free ingredient.  
APM is a methyl ester of two amino acids, L-phenylalanine and L-aspartic acid. It 
was originally discovered by James Schlatter in 1965. After APM is ingested, it is broken 
down in the intestinal tract into 50% phenylalanine, 40% aspartic acid, and 10% 
methanol (Ashok & Sheeladevi, 2014). After absorption into the circulation, 
phenylalanine can be further metabolized to tyrosine. Because phenylalanine is a 
metabolite of APM, individuals who suffer from the genetic condition of phenylketonuria 
should avoid the consumption of APM. Aspartic acid is converted into oxaloacetate and 
alanine. Methanol is further metabolized into formaldehyde by the enzyme alcohol 
dehydrogenase (ADH) and then ultimately into formic acid. The International Agency for 
Research on Cancer has identified formaldehyde as a known human carcinogen 
(“Formaldehyde and Cancer Risk,” 2015). The metabolic fate of APM can be seen below 
in Figure 1.  
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Figure 1: The metabolism of aspartame. ASP=aspartame. PHE=phenylalanine. Figure 
taken from Stegink, 1987.  
 
  Today, APM consumption is deemed to be safe by food regulatory agencies in 
over 100 countries. The acceptable daily intake (ADI) recommended by the United States 
Food and Drug Administration (FDA) is 50 mg/kg body weight/day (“Aspartame,” 
2015). The European Food Safety Authority (EFSA) has set its ADI at 40 mg/kg body 
weight/day. One can of diet soda normally has around 200 mg of APM. Small packets of 
the sweetener typically have around 35 mg and one two-liter bottle of diet soda contains 
around 1100 mg of APM. Therefore, the upper daily limit for an adult weighing 170 
pounds would be three and a half two-liter bottles or 19 cans of diet soda, according to 
the current FDA recommendation. As will be discussed later, several studies have shown 
APM to be associated with negative health effects when consumed at doses much lower 
than what both the FDA and EFSA currently recommend.  
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Aspartame’s Path to FDA Approval 
 
APM was first approved by the FDA in 1974 for dry foods only, but it was not 
until 1981 that the FDA allowed APM to be distributed to the public (“Food and Drug 
Administration,” 1987). Obtaining the approval of APM from the FDA was no easy task 
for G.D. Searle & Company, the producer of APM at the time. From 1973, when Searle 
first petitioned for FDA approval of APM, until 1981, when the FDA gave the green light 
for APM to be consumed by the public, many questionable events took place. In 1973, 
Searle provided the FDA with over 100 studies that attested to the safety of APM. It 
should be noted that all of these studies were fully funded by Searle and that at the time, 
the FDA had no guidelines in place in regards to what sorts of studies are required in 
order to deem a food additive as safe. Dr. Martha Freeman was a physician working in 
the FDA Division of Metabolic and Endocrine Drug Products and a reviewer of the APM 
studies submitted by Searle. She concluded that the studies submitted to the FDA by 
Searle were deficient in regards to exhibiting the safety of APM. In her analyses, she 
cited the lack of vital information on APM such as its chemistry and pharmacokinetics, 
along with many flaws such as how the studies followed no protocols in their design and 
how results were reported very vaguely (Gold, 2002). Dr. J. Richard Crout, who was the 
director of the FDA Bureau of Drugs at the time, also recognized these limitations. 
Despite these findings, APM was given approval by the FDA for use in dry foods in July 
1974. Shortly following that in August 1974, legitimate complaints were filed with the 
FDA asking them to reevaluate their stance on APM and its safety. In July 1975, a special 
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task force was arranged by the FDA commissioner to further investigate the studies done 
on APM by Searle. Preliminary investigations led the FDA to suspend its approval of 
APM in December 1975, before APM distribution to the public had begun. After an in-
depth analysis, the task force found that Searle had omitted a lot of information and facts 
from their studies that would have been detrimental to their case. Examples included not 
reporting the presence of tumors and seizures in animal subjects, editing pathology 
reports, and documenting animals as alive when in fact they had died. In January 1977, 
the FDA launched a criminal investigation into Searle for their falsifications and 
misrepresentations of information related to APM and assigned United States attorney 
Sam Skinner to the case. In the months following, Donald Rumsfeld, a distinguished 
leader in Washington, became the President of Searle, and Sam Skinner ended up moving 
over to Searle’s litigation team. Charges against Searle were eventually dropped. A 
Public Board of Inquiry was formed by the FDA, which firmly came to the conclusion 
that there was still not enough evidence to show that APM is safe for human 
consumption. In July 1981, FDA commissioner Arthur Hull Hayes, who had been 
appointed by Donald Rumsfeld, disregarded the recommendation of the public board and 
officially approved APM for use in dry foods (Gold, 2002). FDA approval of APM was 
further extended for use in carbonated beverages in 1983. In 1996, the FDA ultimately 
approved APM to be used in all foods and beverages.  
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Goals 
 
 Despite numerous studies that have linked APM consumption to a large number 
of adverse health effects, the FDA has yet to conduct a formal reevaluation of its stance 
on the safety of APM use. As will be discussed in detail, the intake of APM has been 
associated with many diseases and conditions such as cancers, metabolic syndrome, 
compromised insulin function, changes in gut microbial balance, increases in oxidative 
stress, depression, memory impairments, and increases in blood glucose. At the same 
time, there are a large number of studies that show APM use by humans to be completely 
safe. In the most recent comprehensive safety review on APM, many of these studies 
were explored (Magnuson et al., 2007). Examination of studies over the past 20+ years 
showed APM consumption to not be associated with carcinogenicity, genotoxicity, 
neurotoxicity, changes in blood glucose, insulin response, behavior, or cognition. Of 
significance, however, is that the sponsor of this APM evaluation was the largest 
manufacturer of APM in the world, Ajinomoto. In an examination of medical literature 
on APM over a period of approximately 20 years, one physician revealed that in 74 
published studies that were funded by APM or APM-related industries, all 74 of them 
had determined APM to be safe (Walton, n.d.). In 91 published studies that were 
independently funded, 84 of these studies had associated APM with harmful health 
effects. The other seven studies that had shown APM to be safe were funded by the FDA, 
which could be argued to be an APM-related industry after seeing how it handled the 
approval of APM. The large discrepancy observed in these findings raises a lot of 
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skepticism about the validity of certain information that is out there in the public 
regarding APM safety. Once a product only aimed at helping diabetics with blood sugar 
maintenance, APM has found its way into the regular diets of millions of people and its 
consumption is predicted to only increase, which is very concerning. The goals of this 
literature review are to inform readers of the multitude of health consequences that can 
result from APM intake, to raise awareness of misleading information that exists on APM 
safety, and hopefully to encourage people to think twice before consuming APM. 
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PUBLISHED STUDIES  	  
 
The Carcinogenic Risk of Aspartame 
 
 The Cesare Maltoni Cancer Research Center in Italy was the first laboratory to 
directly link the consumption of APM to a variety of cancers. Using six different dosages 
of APM, two of which were below the recommended ADI by both the FDA and EFSA, 
researchers incorporated APM into the normal daily diet of 8-week-old Sprague-Dawley 
rats. The rats were fed this diet until they naturally died. There were either 100 or 150 
rats of each sex in each group, including the controls. After their deaths, the rats had 
complete autopsies performed on them as tissues from numerous organs were examined 
(Soffritti et al., 2006).  
 In both the male and female groups, increasing APM consumption showed an 
upward trend in the occurrence of all malignant tumors. The only group that exhibited a 
statistically significant increase in all tumor types was the females who were fed 2,500 
mg/kg body weight/day of APM (p<0.01), a dose much higher than what the FDA 
currently recommends (40 mg/kg body weight/day). An upward trend in both males and 
females was also observed in the occurrence of lymphomas and leukemias. In regards to 
these two specific cancers, statistically significant increases in their prevalence were seen 
again only in females. However in this analysis, five out of the six female groups treated 
with APM had this notable increase (p<0.05 or p<0.01, see Table 2 below). These were 
the females who were fed 5,000, 2,500, 500, 100, and 20 mg/kg body weight/day of 
APM. In the analysis of renal pelvis and ureter tissues, researchers found dose-dependent 
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increases in dysplastic hyperplasias and papillomas in females. Increases were seen in the 
males as well; however, they were not in a dose-dependent manner. Carcinomas of these 
tissues were also observed in both the male and female groups. Only the males who were 
fed 5,000, 2,500, 500 and 100 mg/kg body weight/day of APM exhibited carcinomas, 
whereas carcinomas were present with an upward trend in all the female APM treated 
groups. Among the females, all groups but the 4 mg/kg body weight/day APM treated 
one had statistically significant increases when the total number of carcinomas and 
dysplastic hyperplasias/papillomas were looked at (p<0.05 or p<0.01, see Table 2 below). 
In both the male and female control groups, no carcinomas were found. A total of 21 
carcinomas were found in all the APM-treated groups. Furthermore, the researchers also 
analyzed nervous tissue to look for schwannomas. Malignant schwannomas were 
observed with an upward trend in males. Although the females did not exhibit a similar 
upward trend, a total of 9 malignant schwannomas were seen in all the APM-treated 
females; no schwannomas were seen in the female controls. A summary of all the 
findings discussed above can be seen in Tables 1 and 2 below. 
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Table 1: The occurrence of precancerous and cancerous lesions in male Sprague-Dawley 
rats treated with APM throughout entire life. Table taken from Soffritti et al., 2006.  
 
 
 
Table 2: The occurrence of precancerous and cancerous lesions in female Sprague-
Dawley rats treated with APM throughout entire life. Table taken from Soffritti et al., 
2006.  
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The same laboratory carried out a very similar study in which they evaluated the 
carcinogenic effects of APM when it was given to Sprague-Dawley rats starting in fetal 
life (Soffritti et al., 2007). APM doses of 100 mg/kg body weight/day and 20 mg/kg body 
weight/day were added to the normal diets of female Sprague-Dawley rats and given to 
them starting on day 12 of pregnancy. After their births, the newborn rats continued on 
the APM diets until they naturally died. There were 70 rats of each sex in the control 
groups and 95 rats of each sex in the APM treated groups. Exactly like in the previous 
study, all rats had complete autopsies performed on them after their deaths and tissues 
from many different organs were analyzed (Soffritti et al., 2007).  
 In the males, an increase in the occurrence of malignant tumors was observed 
with increasing APM consumption, with a statistically significant one seen in the group 
fed 100 mg/kg body weight/day of APM (p<0.01). In the females, although not 
statistically significant, an increase in the occurrence of malignant tumors was only seen 
in the 100 mg/kg body weight/day group. Increases in the incidences of lymphomas and 
leukemias were observed in both the males and females with increasing APM dose. The 
increases in both sexes were only statistically significant at 100 mg/kg body weight/day 
(p<0.05 in males, p<0.01 in females). Analysis of mammary gland tissue of both the 
males and females revealed the presence of carcinomas. The female rats exhibited an 
increase in mammary carcinomas with increasing APM dose, with a statistically 
significant increase in the 100 mg/kg body weight/day group (p<0.05). Mammary 
carcinomas were seen in two of the male rats treated with 100 mg/kg body weight/day 
APM. As expected, no mammary carcinomas were found in the male controls. The 
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results of this study further reinforced previous findings on the carcinogenic effects of 
APM and additionally showed that exposure to APM during the fetal period can 
potentiate its harmful effects. Compared to the occurrence of lymphomas and leukemias 
in female rats given APM starting at 8 weeks old (Soffritti et al., 2006), the female rats 
given the same dose of APM beginning in fetal life had a greater occurrence of these 
cancers. This can be seen below in Table 3.  
 
Table 3: Comparing the occurrence of lymphomas and leukemias in female Sprague-
Dawley rats when fed APM postnatally and prenatally. Table taken from Soffritti et al., 
2007. 
 
 
Furthermore, when looking at the female rats that exhibited lymphomas and leukemias in 
both experiments, the researchers observed that those who were fed APM at a dose of 
100 mg/kg body weight/day during fetal life had greater death prevalence than those fed 
the same dose postnatally. This can be seen in Figure 2 below.  
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Figure 2: Prevalence of death in APM-treated female Sprague-Dawley rats who had 
leukemias and lymphomas. Arrows show when APM feeding was started. A. Postnatal 
APM Consumption. B. Prenatal APM Consumption. Figure taken from Soffritti et al., 
2007.  
 
 It is well known that changes in the expression of various oncogenes and tumor-
suppressor genes occur during the initiation and progression of cancers. To investigate 
whether APM has any effect at this molecular level, researchers looked at the expression 
of two oncogenes and one tumor-suppressor gene in mice after they were treated with 
APM. The tumor-suppressor gene examined was p53 and the oncogenes examined were 
Ha-ras and c-myc. The expressions of these genes were looked at in seven different 
organs: lymph nodes, bone marrow, thymus, kidney, liver, spleen, and lung (Gombos et 
al., 2007).  
Five-week old female mice were administered APM by mouth for one week. The 
APM was added to water. Three different doses of APM were used: 40 mg/kg body 
weight, 200 mg/kg body weight, and 2500 mg/kg body weight. There were six mice in 
each dosage group, including the control group. After the one week, all the mice 
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underwent autopsies. The target tissues were examined and the total RNA from each 
tissue was extracted. Using probes specific for Ha-ras, c-myc, and p53, the expression of 
these three genes was determined. The beta-actin gene in each organ was used as the 
control since this gene is constantly expressed. 
Increases in the expression of the p53 tumor-suppressor gene and both the Ha-ras 
and c-myc oncogenes were observed in the lymph nodes, bone marrow, thymus, and 
kidneys of all the APM fed mice. Increased activity of p53 has been observed in a wide 
range of cancers (Bártek et al., 1991). In the liver, spleen, and lung tissues of the APM 
fed mice, the expression of these three genes was only remarkably increased in the 200 
mg/kg body weight APM dose group. The changes in the expression of the Ha-ras, c-
myc, and p53 genes at the various APM doses can be seen in Figure 3 below. It should be 
noted that in the 2500 mg/kg body weight APM dose group, the researchers observed an 
osmotic diarrhea in the mice because of the large osmotic concentration of the APM 
mixture they were fed. This was believed to prevent the absorption of APM into the 
bloodstream and consequently result in a decreased expression of these genes that were 
studied in the various organs.  
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Figure 3: Changes in the expression of c-myc, Ha-ras, and p53 genes in various organs 
of mice treated with three different doses of APM. Gene expression is shown as 
percentage of beta-actin gene activity. Figure taken from Gombos et al., 2007.  
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 In an effort to investigate any link between APM consumption and cancers in 
humans, a study was carried out that looked at the prevalence of hematopoietic and 
malignant brain cancers over the course of five years in people who participated in the 
National Institutes of Health-American Association of Retired Persons (NIH-AARP) Diet 
and Health Study (Lim et al., 2006). In 1995 and 1996, comprehensive food 
questionnaires were sent out to AARP members between the ages of 50 and 71 in eight 
different states. Along with basic information such as age, sex, weight, ethnicity, and 
family and medical history, these questionnaires assessed the frequency at which 
participants drank four different types of APM-containing drinks over the course of a 
year. The four drinks asked about were diet sodas, APM-containing fruit juices and iced 
teas, and APM that was added to coffee and tea. The questionnaire also asked about the 
consumption frequency of 124 different foods over the course of a year. However, the 
APM content of these foods, if any, was not taken into account in the determination of 
APM intake of these individuals. The participants had to answer these questions by 
estimating their consumption of these products from “never” to “greater than six times a 
day.” In addition to inquiring about food and drink habits, the researchers gathered 
information regarding people’s lifestyles. The factors looked at were activity level, 
alcohol usage, smoking history, and caffeine intake. After the gathering of this 
foundational information, daily APM intake for 285,079 men and 188,905 women was 
estimated. None of the participants had any prior history of cancer. 
 After looking at the incidence of all hematopoietic cancers and malignant gliomas 
in these men and women for the next five years, no relationship was found between APM 
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consumption and the occurrence of these cancers. There were six groups of people 
examined, ranging from no reported APM intake to an APM intake of > 600 mg/day. In 
the analysis, age, sex, body mass index (BMI), ethnicity, and history of diabetes were 
adjusted for using Cox proportional hazards models. With these adjustments, for all 
hematopoietic cancers in men and women combined, the relative risk (RR) for the largest 
APM consuming group, > 600 mg/day, was determined to be 0.98, 95% Confidence 
Interval (CI) [0.76 – 1.27]. For malignant gliomas in men and women combined, the RR 
for the largest APM consuming group was determined to be 0.73, 95% CI [0.46 – 1.15]. 
Even in the lowest APM consuming group of men and women, < 100 mg/day, there was 
no significant relationship found between APM use and the occurrence of these cancers. 
For all hematopoietic cancers in this group, the RR was 0.91, 95% CI [0.81 - 1.03], and 
for malignant gliomas, the RR was 0.99, 95% CI [0.75 - 1.29]. In a more detailed 
analysis, the researchers adjusted additionally for activity level, family history of cancer, 
smoking history, alcohol usage, and daily caloric and caffeine intake. They found a less 
than 10% change in their results across both genders and all ages. Although the changes 
were not specifically presented in the study, it was determined that these variables 
contributed minimally to the overall incidence of the cancers examined. In conclusion, no 
association was found between APM intake and the incidence of hematopoietic cancers 
and malignant gliomas (Lim et al., 2006).  
 On the contrary, in a different study that also used surveys to assess the APM 
consumption of humans over a period of time, APM was linked to an increased risk of 
several cancers (Schernhammer et al., 2012). Participants in two different groups, the 
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Nurses’ Health Study (NHS) and the Health Professionals Follow-up Study (HPFS), 
completed questionnaires that assessed how much APM they had consumed in the past 
year. The weight, height, smoking history, alcohol use, medical history, activity level, 
multivitamin use, and consumption frequency of approximately 130 foods of the 
participants was also recorded. Unlike the previous questionnaire study, the frequency of 
regular soda consumption was also assessed. Three APM-containing beverages were 
asked about: diet coke with caffeine, diet coke without caffeine, and any other diet soda. 
Participants were given several answers to choose from ranging from “never” to “greater 
than or equal to six times a day.” People in the NHS were female nurses between the ages 
of 30 and 55. Data collection from the NHS began in 1984. People in the HPFS were 
male health professionals between the ages of 40 and 75. Data collection from the HPFS 
began in 1986. The APM and food consumption of the participating individuals was 
reassessed every four years to account for changes in peoples’ drinking and eating habits. 
Every two years, the participants updated their medical histories and reported any new 
diagnoses. The gathering of all this information from both groups continued until 2006, 
or until an individual was either first diagnosed with cancer or passed away. The data 
from men and women was kept separate in order to account for any potential gender 
differences in cancer onset.  
 Information gathered from a total of 47,810 men and 77,218 women was used to 
look at the relationship between APM consumption and various cancers. Using Cox 
proportional hazards models, the following variables were adjusted for: age, race, BMI, 
activity level, smoking habits, alcohol intake, daily caloric intake, multivitamin usage, 
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menopause and hormone replacement therapy (in women), and fruit, vegetable, sugar, 
animal protein, and saturated fat intakes. In men, APM intake was observed to result in 
an increased risk of developing Non-Hodgkin lymphoma (NHL) and multiple myeloma. 
In the group of men who drank > 1 serving of diet soda/day, the RR for NHL was 1.31, 
95% CI [1.01 – 1.72]. For multiple myeloma, the RR was 2.02, 95% CI [1.20 – 3.40]. For 
men who consumed > 2 servings of diet soda/day, the RR for NHL was even higher at 
1.69, 95% CI [1.17 – 2.45]. In the women, there was no indication that APM 
consumption resulted in an increased risk of developing NHL and multiple myeloma. 
However, when the relationship between APM consumption and leukemia was analyzed, 
it was seen that both men and women who ingest APM are at an increased risk. When the 
data from both sexes was combined, the RR for those who drank > 1 serving of diet 
soda/day was determined to be 1.42, 95% CI [1.00 – 2.02]. Similar findings in the 
occurrence of NHL, multiple myeloma, and leukemia in both men and women were 
observed when those who drank regular soda were compared to those who did not drink 
any kind of soda. In summary, greater intakes of APM were linked to increased 
prevalence of NHL and multiple myeloma in men and leukemia in both men and women 
(Schernhammer et al., 2012).  
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Aspartame’s Association with Metabolic Disturbances and Diabetes  
 
 Several studies have shown that APM consumption can contribute to metabolic 
disturbances and the onset of type 2 diabetes. To look at this relationship, information on 
the diet and lifestyle habits of men and women in the Multi-Ethnic Study of 
Atherosclerosis (MESA) population was gathered (Nettleton et al., 2009). The goal of the 
study was to determine if diet soda intake puts people at a higher risk for developing type 
2 diabetes, metabolic syndrome, or any of the conditions of metabolic syndrome. 
Individuals with a fasting glucose of  >126 mg/dl and those on diabetic medications were 
classified as type 2 diabetics. Metabolic syndrome was identified in participants as the 
occurrence of three or more of the following measurements: waist circumference > 102 
cm in men or > 88 cm in women, HDL cholesterol < 40 mg/dl in men or < 50 mg/dl in 
women, blood triglycerides > 150 mg/dl, fasting glucose > 100 mg/dl (or diabetic 
medication treatment), and blood pressure > 130/85 mmHg (or blood pressure medication 
treatment) (Grundy et al., 2005).  
The MESA population consisted of men and women in six different states 
between the ages of 45 and 84 who were Caucasian, African American, Hispanic, or 
Chinese. Baseline information was gathered from 2000-2002. Data was reevaluated three 
times following the initial collection: in 2002, 2004, and 2005. Participants were asked to 
estimate their diet soda consumption ranging from “rarely/never” to “greater than 6 times 
a day”. A detailed breakdown of their food intake, many lifestyle routines, and complete 
medical histories were also gathered. Furthermore, at each of the four data collection 
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times, fasting glucose, fasting insulin, waist circumference, blood pressure, triglycerides, 
and HDL cholesterol were measured. There were 5,011 participants in this study, none of 
which were diabetic or prediabetic. However, it should be noted that at the start of the 
study some participants had certain aspects of metabolic syndrome.  
In the data analysis, all adjustments were made using Cox proportional hazards 
models. After adjusting for demographics, caloric intake, and lifestyle factors, 
consumption of > 1 serving of diet soda daily was shown to result in a 36% increased risk 
of developing metabolic syndrome and a 67% increased risk of developing type 2 
diabetes. When further adjustments were made for BMI and waist circumference, a 
statistically significant increased risk of 38% remained for type 2 diabetes. However, no 
significant relationship between diet soda intake and metabolic syndrome was observed 
after these additional adjustments. This can be seen in Table 4 below in models 2, 3, and 
4. Looking at the individual components of metabolic syndrome, diet soda intake was 
linked only to increases in waist circumference and blood glucose. For those drinking > 1 
serving/day, the hazard ratio (HR) was 1.59, 95% CI [1.23 – 2.07] for waist 
circumference. The HR for fasting blood glucose was 1.28, 95% CI [1.08 – 1.52]. These 
results were determined after making the Model 2 adjustments, which are shown in Table 
4 below. 
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Table 4: The association between diet soda intake and risk of developing metabolic 
syndrome or type 2 diabetes in people from the MESA population. Table taken from 
Nettleton et al., 2009.  
 
Whenever humans are used as subjects, there can be a large number of variables 
that unknowingly contribute to observed results. To more directly look at the effects of 
APM on metabolic parameters, researchers in one particular study used animals to 
investigate this topic (Palmnäs et al., 2014). Chronic low-dose APM treatment in 
Sprague-Dawley rats was found to be associated with increased blood glucose, 
compromised insulin function, and a shift in gut microbial balance (Palmnäs et al., 2014). 
APM was administered to the rats in water at a dose of 5-7 mg/kg body weight/day, a 
dose much less than the ADI recommended by both the FDA and EFSA. This treatment 
was done for eight weeks. For the two weeks prior to the start of APM treatment, the rats 
were put on either a normal chow diet or a high fat diet. Each diet type had a control 
group with no APM consumption; therefore, there were a total of four rat groups 
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examined, with 10-12 rats in each group. At the end of the ten weeks, all the rats were 
sacrificed.  
During the eighth week of the experiment, fasting blood glucose levels of all rats 
was obtained. In both the chow diet and high fat diet APM-treated groups, blood glucose 
levels were higher compared to the controls. Average blood glucose was 5.4 ± 0.2 mM in 
the chow diet control group, whereas in the APM-treated chow diet group it was 6.9 ± 0.4 
mM, a statistically significant increase (p<0.05). In the high fat diet control group, 
average blood glucose was 5.6 ± 0.2 mM. The average in the APM-treated high fat diet 
group was 7.4 ± 0.6 mM, also a statistically significant increase (p<0.05). During the 
ninth week, insulin tolerance tests were performed. The average blood glucose levels of 
the APM-treated rats remained notably higher than those of the control rats throughout 
these tests. This disparity was determined to be statistically significant (p<0.05) and can 
be seen in Figure 4 below.  
 
 
 
 
 
 
Figure 4: Average Blood Glucose in Sprague-Dawley Rats after Insulin Tolerance Test. 
† p<0.05. CHW=chow diet with water, CHA=chow diet with APM, HFW=high fat diet 
with water, HFA=high fat diet with APM. Figure taken from Palmnäs et al., 2014.  
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 At the end of the tenth week, fecal samples were collected from all the rats. DNA 
was extracted from these samples and microbial analyses were performed. Of 
importance, a statistically significant increase (p<0.05) in the proportion of 
Enterobacteriaceae was found in the APM-treated high fat diet group compared to the 
control high fat diet group. Previous studies have shown that Enterobacteriaceae 
generate short-chain fatty acids (SCFA) and gases that contribute to insulin resistance and 
intestinal inflammation (Koren et al., 2012). As part of their symbiotic relationship, gut 
microorganisms are known to generate many metabolites (Tremaroli & Bäckhed, 2012). 
Serum samples from all the rats were obtained in order to evaluate a large number of 
these metabolites. In both the APM-treated diet groups, blood propionate levels were 
found to be approximately 2.5x greater than those in the controls, a statistically 
significant increase (p<0.05). Propionate is a SCFA that is produced by bacteria in the 
gut. Once produced in the colon, it enters the circulation and travels to the liver where it 
induces gluconeogenesis, which ultimately raises blood glucose levels. Propionate has 
also been linked to insulin resistance (Kimura et al., 2013). In summary, low-dose APM 
administration in rats was associated with increased blood glucose levels and decreased 
insulin function. These changes can possibly be attributed to increases in propionate 
production as a result of changes in the gut microbial population.  
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The Role of Aspartame in Oxidative Stress 
 
Oxidative stress is a disruption in the balance of reactive oxygen species (ROS) in 
the body and the body’s antioxidant defense mechanisms. Increases in ROS and/or 
decreases in antioxidant defenses have been implicated in a large spectrum of diseases 
(Aruoma, 1998). Methanol, which is one of the breakdown products of APM, has 
previously been shown to result in the generation of ROS (Castro et al., 2002). To 
determine whether long term APM consumption can produce similar effects, one study 
looked at markers of free radical stress in rats being treated with APM. It was found that 
APM intake can not only lead to increased oxidative stress in the brain, but also can give 
rise to apoptosis in the brain (Ashok & Sheeladevi, 2014).  
 Rodents naturally have high folate levels in their liver. This results in the rapid 
metabolism of formate and therefore prevents accumulation of this APM-derived 
compound in the blood. In order to create a folate-deficient environment similar to that in 
humans, male Wistar strain albino rats were treated with methotrexate (MTX) and fed a 
diet absent of folate prior to being given APM (Ashok & Sheeladevi, 2014). APM was 
combined normal saline solution and given to the MTX-treated rats at a dose of 40 mg/kg 
body weight/day, the ADI recommended by the EFSA and a dose lower than what the 
FDA recommends. APM treatment lasted for 90 days. Rats were divided into three 
groups of six. One group was the normal saline control, one was the MTX-treated 
control, and the other was the MTX-treated rats who were fed APM. After the 90-day 
treatment period all the rats were sacrificed.  
	  26 
 Superoxide dismutase (SOD) is a vital antioxidant enzyme that gets rid of 
superoxide radicals in cells. Increases in the activity of this enzyme were observed in the 
APM-treated rats (Ashok & Sheeladevi, 2014). These increases were present in six 
different regions of the brain: hippocampus, pons-medulla, midbrain, cerebellum, 
cerebral cortex, and hypothalamus. Increases in the activity of catalase and glutathione 
peroxidase, two other important antioxidant enzymes, were also observed in all six of 
these brain regions of the APM-treated rats. Glutathione is an endogenous compound that 
functions as an antioxidant. In its reduced form it is able to donate an electron to ROS 
and subsequently alleviate the harmful effects of these species. In the six brain regions 
analyzed, there were decreased concentrations of reduced glutathione in the APM-treated 
rats. It has been shown that reduced glutathione is a necessary cofactor in the metabolism 
of methanol (Pankow & Jagielki, 1993). When plasma methanol concentrations of the 
rats were measured, significantly higher levels of methanol were present in the APM-
treated rats, which could explain the decreased amounts of reduced glutathione observed 
in the brain. Rather than scavenging ROS, this major antioxidant had to be utilized to 
breakdown methanol. After reduced glutathione donates an electron, glutathione 
reductase is responsible for converting it back into its reduced state. In the six brain 
regions studied in the APM-treated group, decreased activity levels of this enzyme were 
also observed. These decreases could have also been responsible for the decreased 
amounts of reduced glutathione in the brain. Glutathione-S-transferase, a detoxification 
enzyme that conjugates reduced glutathione to other compounds, was found to have 
increased activity in all six of the brain regions looked at in the APM-treated rats. All the 
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changes discussed above in the APM-treated rats were found to be statistically significant 
in their comparison to both control groups (p<0.05) (Ashok & Sheeladevi, 2014). 
 In the presence of free radicals, polyunsaturated lipids in the membranes of cells 
can become oxidized (Bergendi et al., 1999). This can compromise the structural and 
functional integrity of cell membranes and ultimately lead to impaired cell function 
(Halliwell, 1992). Increased levels of lipid peroxidation were found in all six analyzed 
brain regions of the APM-treated rats compared to the controls. These increases were 
determined to be statistically significant (p<0.05). To look at the amount of protein 
oxidation in tissues that results from interactions with ROS, protein carbonyl levels are 
assessed (Beal et al., 1993). Oxidative stress in the brain has also been shown to result in 
lowered levels of protein thiols (Patsoukis et al., 2004). Increased protein carbonyl levels 
and decreased protein thiol levels were found in all six analyzed brain regions of the 
APM-treated rats as well. These changes were determined to be statistically significant 
when compared to the controls (p<0.05) (Ashok & Sheeladevi, 2014). 
 Bcl-2, Bax, and caspase-3 are three genes that are involved in the regulation of 
apoptosis. Bcl-2 is involved in the prevention of apoptosis whereas Bax and caspase-3 are 
involved in its promotion. The mRNA expression of these three genes was determined in 
four different brain regions of the rats: cerebral cortex, cerebellum, hippocampus, and 
hypothalamus (Ashok & Sheeladevi, 2014). In the APM-treated rats, Bcl-2 was found to 
have decreased expression and both Bax and caspase-3 were found to have increased 
expression in all four of these brain regions. The protein expression of these three genes 
was also determined. In the APM-treated rats, Bcl-2 protein expression was decreased in 
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the cerebral cortex, cerebellum, and hippocampus. Protein expression of Bax and 
caspase-3 were both increased in these three brain regions of APM-treated rats. In the 
analysis of both mRNA and protein expression of these genes, the beta-actin gene was 
used as the control since it is constantly expressed. All the changes in mRNA and protein 
expression were determined to be statistically significant when compared to the controls 
(p<0.05). The large number of findings in this study showed that relatively long-term 
APM consumption at the current recommended daily dose (by the EFSA) can induce a 
great deal of oxidative stress in the brain and lead to alterations in apoptotic mechanisms 
at the genetic level which ultimately lead to cell death in the brain (Ashok & Sheeladevi, 
2014).  
 The intake of APM has also recently been shown to induce oxidative stress in the 
red blood cells (RBC) of rats (Prokic et al., 2014). APM mixed into distilled water was 
administered to five male Wistar albino rats at a dose of 40 mg/kg body weight/day for 
six weeks. The control group also contained five rats. At the end of the six weeks all the 
rats were sacrificed, at which time blood samples were acquired.  
 In the APM-treated group, increased levels of superoxide anion and hydrogen 
peroxide were found in the RBCs, both important indicators of oxidative stress. 
Peroxynitrite is a strong oxidant that is generated by the reaction of superoxide anion and 
nitric oxide, an endogenous free radical produced by endothelial cells. Considerably 
higher levels of peroxynitrite were found in the RBCs of the APM-treated rats. 
Furthermore, greater amounts of lipid peroxidation were observed in the RBCs of the 
APM-treated rats (Prokic et al., 2014). Reduced glutathione plays an important role in 
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RBCs, as it is able to reduce free radicals. In the APM-treated rats, increased 
concentrations of this compound were found in RBCs, indicative of a higher level of 
oxidative stress. Also observed in the RBCs of the APM-treated rats were increased 
activity levels of catalase, an antioxidant enzyme that breaks down hydrogen peroxide. 
All of the changes presented above that occurred in the RBCs of the APM-treated rats 
were statistically significant when compared to the control group (p<0.05) (Prokic et al., 
2014). 
 In addition to looking at markers of oxidative stress in the RBCs, the researchers 
measured the serum levels of glucose, triglycerides, and cholesterol in both groups at the 
end of the six weeks. In the APM-treated rats, average levels of all three of these 
compounds were elevated (Prokic et al., 2014). This can be seen below in Table 5.  
 
Table 5: Serum concentrations of glucose, cholesterol, and triglycerides in the control 
and APM-treated rats. ASP = aspartame. Numbers presented as averages ± standard 
error. * p<0.05 compared to control. Table taken from Prokic et al., 2014.  
 
 
 
 
 
 
Previous studies have shown that increased glucose, cholesterol, and triglyceride 
levels in the blood activate neutrophils (Kummer et al., 2007; Petnehazy et al., 2006; 
Alipour et al., 2008). The increased affinity of these neutrophils for the endothelium 
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results in the generation of ROS that can then enter RBCs and give rise to oxidative stress 
(Lynch & Fridovich, 1978). The pro-oxidative changes seen in this experiment reinforced  
the likelihood that APM has damaging effects on oxidative stress and metabolic 
parameters when consumed at the current EFSA recommended daily dose of 40 mg/kg 
body weight/day (Prokic et al., 2014).  
 
Changes in Neurological Behavior, Function, and Chemistry due to Aspartame 
 
The consumption of APM has been linked to several impairments in brain 
function both at a behavioral level and at a molecular one (Abdel-Salam et al., 2012a, 
2012b; Lindseth et al., 2014). In one human study, APM intake was found to be 
associated with poorer performance on spatial ability tests and worsened moods and 
depression (Lindseth et al., 2014). In a double-blind setup, 28 young healthy adults were 
fed a strict low-APM diet of 10 mg/kg body weight/day for one eight day period and a 
strict high-APM diet of 25 mg/kg body weight/day for another eight day period. After the 
first APM treatment period and before the next one, participants went back to their 
normal diets for two weeks. All participants were given specific instructions and 
informed of the importance of consuming only the foods and drinks assigned during the 
treatment periods. In order to assess spatial abilities, the Vandenberg Mental Rotation 
Test was administered. In this test, participants were required to differentiate between 
various geometrical shapes. Scores were assigned based upon the number of correct 
answers in a six-minute period. Zung’s Irritability Subscale and Self-Rating Depression 
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Scale tests were administered to assess mood and depression, respectively. All three of 
these mental tests had previously been shown to provide reliable results (Vandenberg & 
Kuse, 1978; Campbell et al., 2012; Sakamoto et al., 2001). All tests were given to the 
participants within two hours of their last meal in each eight day APM-treatment period.  
The scores of the participants on the spatial ability test were notably higher after 
they consumed the low-APM diet compared to their scores after the high-APM diet. This 
difference was of statistical significance (p<0.05). Scores obtained from the Zung tests 
showed that after the participants were fed the high-APM diet they were much more 
depressed and irritable compared to how they felt after being fed the low-APM diet. 
These differences were also of statistical significance (p<0.01). Of the 28 participants, 
three had scores that put them in the clinically depressed category; none of the three had 
any prior history of depression. It should be noted that the APM dose of 25 mg/kg body 
weight/day administered in the high-APM diet of this study was half the ADI that the 
FDA currently recommends. Although the findings in this study do not prove that APM 
causes these neurobehavioral impairments, the contribution of APM to depression, 
irritability, and impaired spatial abilities seen in these subjects cannot be overlooked 
(Lindseth et al., 2014).  
One animal study found APM intake to be associated with decreased memory 
retention and changes in the levels of several important neurotransmitters (Abdel-Salam 
et al., 2012a). Male Swiss albino mice were given APM subcutaneously once a day at a 
dose of 0.625, 1.875, or 5.625 mg/kg body weight for two weeks. There were six mice in 
each dose group and in the control group, which was administered normal saline. In order 
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to assess the memory of the mice, the Morris water maze was used. This was a maze that 
required the mice to locate a platform that was submerged underwater in an unknown 
location. Once the mice were able to locate it, they could leave the water tank. Three 
trials were conducted each time this test was done. In the first trial, the mice were kept on 
the platform for 15 seconds after finding it in order to process its location. In the next two 
trials, the mice were able to leave the tank after successfully locating the platform, which 
remained in the same spot. Throughout the two weeks of APM administration, this test 
was done four times a week.  At the end of the two weeks all the mice were sacrificed 
and brain tissues were analyzed. 
 Dose-dependent increases in the average time required to locate the platform in 
the first trial were observed in all three of the APM-treated groups over the two weeks, 
with a statistically significant increase in the 5.625 mg/kg APM dose group (p<0.05). 
Average time in the control group was 3.58 ± 0.27 sec. In the 5.625 mg/kg APM group it 
was 5.65 ± 0.66 sec. This can be seen in Figure 5 below. In the second and third trials of 
each test done, no statistically significant changes in the average time required to locate 
the platform were observed across the APM-treated groups.  
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Figure 5: Average time required for APM-treated mice to find a submerged platform in 
the first trial of the Morris water maze. Data was acquired from eight tests performed 
over the course of two weeks. * p<0.05 compared to control. Figure taken from Abdel-
Salam et al., 2012a.  
 
 The amount of the reduced glutathione present in the brain tissue of the APM-
treated mice decreased in a dose-dependent manner. A 25.1% decrease was observed in 
the 1.875 mg/kg group and a 32.7% decrease in the 5.625 mg/kg group, both statistically 
significant when compared to the control (Abdel-Salam et al., 2012a). Previous studies 
have linked decreases in the levels of this important brain antioxidant to impairments in 
spatial memory (Dean et al., 2009). Decreases in the brain levels of serotonin, dopamine, 
and noradrenaline were also observed in a dose-dependent fashion in the APM-treated 
rats. In the 1.875 and 5.625 mg/kg APM dose groups, these changes were statistically 
significant compared to the control (p<0.05) (Abdel-Salam et al., 2012a).  
 Changes in the levels of these monoamine neurotransmitters were again observed 
by these researchers when mice were administered APM in a different study design 
(Abdel-Salam et al., 2012b). Two different controls were used in this study: one with 
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normal saline and one with bacterial lipopolysaccharide. Lipopolysaccharide was used in 
order to see the effects of APM when systemic inflammation is present, a condition 
triggered by this compound. Inflammation is an underlying feature of a wide spectrum of 
diseases and has been shown to deteriorate neurons (Qin et al., 2007). Both normal saline 
and lipopolysaccharide were administered intraperitoneally. The lipopolysaccharide 
treated mice received APM in the following doses: 0.625, 1.875, 5.625, 11.25 and 22.5 
mg/kg body weight. The saline treated mice received doses of 11.25, 22.5, and 45 mg/kg 
body weight. Each treatment group contained six mice. APM was administered as a 
single dose subcutaneously and after four hours all the mice were sacrificed.  
 Dose-dependent decreases in the levels of serotonin, dopamine, and noradrenaline 
were observed in the brains of all the mice treated with APM. Compared to the saline 
control, the lipopolysaccharide control group had significantly higher levels of these 
neurotransmitters. This was expected as previous studies had shown this inflammatory 
substance to be associated with these increases (Borowski et al., 1998; Mori et al., 2003; 
Ota et al., 2007). APM administration to the lipopolysaccharide reduced the increase of 
these neurotransmitters. All observed changes were found to be statistically significant 
(p<0.05) (Abdel-Salam et al., 2012b). Data obtained from all the groups can be seen 
below in Table 6.  
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Table 6: Serotonin, Dopamine, and Noradrenaline levels in the brains of mice treated 
with APM, Lipopolysaccharide, and APM with Lipopolysaccharide. Numbers presented 
as averages ± standard error. * p<0.05 when compared to saline control. + p<0.05 when 
compared to lipopolysaccharide control. Table taken from Abdel-Salam et al., 2012b. 
 
The effects of APM metabolites on the brain explain these changes that occur at 
the neurochemical level (Humphries et al., 2008). Once phenylalanine, one of the 
metabolites of APM, enters the vasculature, it is either further metabolized into tyrosine 
in the liver or transported across the blood-brain barrier (BBB) via a neutral amino acid 
transporter (NAAT). The NAAT is also responsible for the transport of six other amino 
acids across the BBB. Tyrosine, a precursor for dopamine, and tryptophan, a precursor 
for serotonin, are two of the amino acids that compete with phenylalanine for entry into 
the brain using this transporter. If the level of one amino acid is elevated compared to that 
of another one, it will reduce the entry of the other amino acids into the brain because 
they all compete for the same site on the NAAT. APM consumption has been shown to 
increase the concentration of phenylalanine in the blood (Jr & Stegink, 1988). Therefore, 
if too much phenylalanine is present in the blood as a result of APM intake, it will 
prevent adequate amounts of tyrosine from crossing the BBB and consequently result in 
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decreased dopamine synthesis in the brain. Tyrosine transport across the BBB is the only 
method by which tyrosine can be present in the brain; tyrosine synthesis does not occur in 
the brain. Since dopamine is a precursor of noradrenaline, decreases in dopamine will 
consequently lead to decreases in noradrenaline as well. The same mechanism explains 
the lowered levels of serotonin in the brain that can result from APM intake. With the 
increased blood levels of phenylalanine, less tryptophan can enter the brain via the 
NAAT and less serotonin is synthesized. The decreased amounts of serotonin can result 
in lowered activity of cyclic adenosine monophosphate (cAMP) at the BBB (Humphries 
et al., 2008). Sufficient cAMP is important in maintaining the structural integrity of the 
BBB; therefore, decreases in cAMP will weaken the function of this important barrier. A 
schematic showing the effects of decreased serotonin levels can be seen in Figure 6 
below. 	   	  
 
 
 	  	  	  	  	  	  	  	  	   	  	  	  	  	  
Figure 6: The effects of lowered serotonin levels on the blood-brain barrier. Figure taken 
from Humphries et al., 2008.  	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Furthermore, since gamma-aminobutyric acid (GABA) transporters on astrocytes are 
serotoninergic receptors, decreased serotonin levels can down-regulate these transporters 
that are responsible for the reabsorption of GABA back into astrocytes. This would result 
in higher levels of GABA in the synaptic cleft and consequently greater and longer 
inhibition of the postsynaptic cell (Humphries et al., 2008).  	  
 	  
	  38 
DISCUSSION 
 
The association of APM intake to a variety of adverse health effects raises 
concern over the consumption of this artificial sweetener that is currently deemed safe for 
humans by the FDA and a large number of other food regulatory agencies around the 
world. Although numerous conflicting studies exist regarding the influence of APM on 
the prevalence of many conditions such as cancer and diabetes, the fact that there are 
studies showing APM intake playing a role in disease development either directly or 
indirectly is a red flag for its use. 
In 2006 and 2007, two separately conducted studies showed APM consumption to 
be related to the increased prevalence of several cancers: lymphomas, leukemias, 
carcinomas of the renal pelvis and ureter, and schwannomas (Soffritti et al., 2006, 2007).  
Being that it was the first time that this connection was experimentally shown, it caught 
the attention of many people, including the FDA. The FDA conducted a review of the 
studies and then released a statement in which they maintained their stance that APM use 
at an intake of up to 50 mg/kg body weight/day is safe. In the statement, the FDA said 
that many flaws were present in the study in regards to its design, data collection, and the 
reporting of its findings (FDA, 2007). However, no specifics were mentioned in regards 
to what was flawed in the study design. It was stated that many other variables could 
have contributed to the onset of these cancers, such as infections, and that the cancerous 
histological changes observed were not analyzed properly and all occurred by chance. 
The FDA ended the statement by referencing previous studies that had shown no link 
between APM intake and carcinogenesis. Overall, it was a short and vague statement 
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lacking any sound scientific backing. In a different article that aimed to invalidate the 
findings of Soffritti et al., it was mentioned that the APM doses reported in the studies 
were inaccurate, that certain data from the pregnancy period of the rats was missing, that 
the cancer occurrences were in the range of historical controls, and that infection was 
most likely the reason of carcinogenesis in the rats, the same belief held by the FDA 
(Magnuson & Williams, 2008). Of great importance, the authors of this article received 
full financial backing for the presentation of this information from the world’s largest 
producer of APM, Ajinomoto. Therefore, these statements should be interpreted with 
caution.  
In regards to the design of the Soffritti studies, they were the first experiments 
done that examined the relationship between APM and cancer in which APM was 
administered throughout the life of the animals and large treatment and control groups 
were used (Soffritti et al., 2006, 2007). Compared to short-term APM treatment, looking 
at the effects of APM across the life span of animals gives a clearer insight into the 
chronic effects of this artificial sweetener. The slower progressing diseases and biological 
changes that could potentially be related to its use can be better observed. This feature of 
the study, combined with the large number of rats in each treatment group, improved the 
sensitivity of the results. In the rats that began exposure to APM starting in fetal life, the 
prevalence of lymphomas and leukemias in both males and females was almost double 
the prevalence seen in the controls (Soffritti et al., 2007). Although these differences 
were observed in only the 100 mg/kg body weight dose group, a dose higher than what is 
currently recommended in humans, these significant findings cannot be ignored and 
	  40 
should not be compared to historical controls from studies that had different designs and 
did not assess the impact of APM intake over a life span. Furthermore, a total of 21 renal 
pelvis and ureter transitional cell carcinomas were observed in the rats that began APM-
consumption at 8 weeks old. In the past 20 years at the lab at which this study was 
conducted, zero cases of these carcinomas had ever been diagnosed in over 4,000 animals 
that were experimented on (Soffritti et al., 2006).  
Pathology working groups consist of highly skilled pathologists who convene in 
order to conduct an impartial review of existing pathological findings and diagnoses 
made in previous studies. In 2011, one such group reviewed studies done at the 
laboratory at which the Soffritti experiments were carried out and determined all their 
cancer diagnoses to be accurate (Soffritti et al., 2014), contrary to what was believed by 
the FDA. If infections were the only source of carcinogenesis in the rats, then the control 
rats would have incidences of cancer similar to those rats in the APM-treated groups, 
which was not the case as there were notable differences between the two. Additionally, 
even if the doses were not completely accurate as is believed by Magnuson et al., the 
increases in total malignant tumors, lymphomas, leukemias, carcinomas, and 
schwannomas seen in the rats that consumed APM raises a lot of worry about the dangers 
of APM use. Further studies need to be carried out in order to gain a better understanding 
between the relationship of APM and carcinogenesis. These studies should assess APM 
exposure both over life spans and starting in the prenatal period. The findings by Soffritti 
et al. that prenatal exposure potentiates the harmful effects of APM are very concerning 
regarding the use of APM by pregnant women.  
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The large number of products that contain APM as an ingredient makes it very 
difficult to assess human APM intake. From familiar sources such as sodas, yogurts and 
desserts, to less familiar ones such as condiments, coffee syrups and pharmaceuticals, 
APM is present in a wide variety of frequently consumed products. The amount of APM 
people believe to be consuming vs. the amount they actually are consuming can 
potentially vary greatly. This adds a gray area in human studies in which people have to 
recall and estimate APM intake and is one reason why conflicting studies exist when 
humans are used as subjects.  
In the NIH-AARP Diet and Health Study, cancer-free individuals completed a 
food questionnaire that assessed the frequency of APM intake from beverages over the 
course of a year. The participants of the study were then monitored over the next five 
years for occurrences of cancers. After the five year period and data analysis, it was 
determined that there was no association between APM consumption and increased risk 
of hematopoietic and brain cancers (Lim et al., 2006). The design of this study had 
several inherent flaws. Even though self-reported individual and lifestyle factors such as 
ethnicity, smoking history, activity level, and family history of cancer were all adjusted 
for in the analyses, to assess participants for APM consumption only once and then 
extrapolate that information over the next five years is a very inadequate way to 
determine what effects APM has on people’s health. In the initial questionnaire, it is 
possible that errors in the reporting of APM intake occurred. Participants had to 
remember how frequently certain beverages were consumed over a year, a measurement 
method of APM intake that is prone to recall bias. In the five years that the participants 
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were observed, it is likely that their drinking, eating, and lifestyle behaviors changed. 
These changes would have not only impacted estimated APM consumption but also 
added even more variables that could have contributed to the results. Furthermore, the 
questionnaire only asked about APM intake through beverages, so any APM that was 
being consumed through foods was never accounted for. The poor construction of this 
study and the large number of confounding variables present made it difficult to examine 
any direct effects APM has on the health of the participants.  
A similar study using questionnaires was described in the NHS and HPFS review 
that determined APM intake to be associated with an increased risk of NHL and multiple 
myeloma in men and leukemia in both men and women (Schernhammer et al., 2012). The 
questionnaires in this study were updated every four years over the 20 years that the 
study was conducted. Although this gave a more precise estimate of APM consumption 
through diet sodas, the design was still prone to recall bias, omission of other products 
that contain APM, and transient changes in the drinking and eating behaviors of the 
individuals during the study period. One strength of the study is that data collection 
began right after APM was approved for use in beverages in the early 1980s, which 
allowed investigation of a population who had never been exposed to APM. However, 
except for in diet coke, all other diet beverages contained a mixture of APM and 
saccharin up until 1992 when APM became the predominantly used artificial sweetener 
in diet beverages. This makes it difficult to single out APM as the cause of any perceived 
negative health effects. The gender differences in the results could have possibly been 
due to increased activity levels of ADH in men compared to those in women (Chrostek et 
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al., 2003). Since ADH converts one of the metabolites of APM, methanol, to 
formaldehyde, men could have been exposed to higher levels of this known human 
carcinogen; formaldehyde has been linked to leukemias and a variety of other cancers in 
humans (“Formaldehyde and Cancer Risk,” 2015). Further studies that investigate 
whether the differences in ADH activity in males and females are enough to be a 
contributing factor to gender differences in carcinogenesis are warranted. Although this 
particular study using human subjects showed that there is a possibility that APM use can 
increase cancer risk, it was inconclusive because of the great number of confounding 
variables that could not be controlled for and may have influenced the results.  
When the MESA population was examined over a period of seven years, diet soda 
consumption was found to be associated with increased waist circumference, fasting 
blood glucose, and risk of developing type 2 diabetes (Nettleton et al., 2009). Similar to 
the two previous human studies discussed, weaknesses of this study included the use of 
questionnaires to estimate APM consumption and the fact that a variety of lifestyle 
variables and substances in diet sodas, including other artificial sweeteners, could have 
influenced the findings. Simply because consumption of diet sodas was found to be 
associated with these symptoms does not in any way provide legitimate evidence that 
they are causing these changes. When people drink calorie-free diet soda, it is possible 
for them to consume a greater number of calories from other foods and drinks than those 
calories they saved from drinking the diet soda. An increase in daily caloric intake is one 
possibility for the larger waist circumferences found in the population that was 
consuming diet soda. The questionnaire used in this study included a detailed assessment 
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of the categories of foods that participants typically ate; however, as is always possible, 
their eating habits could have considerably changed over the course of the study. Given 
the fact that the types of foods consumed can greatly influence fasting blood glucose and 
therefore the risk of developing type 2 diabetes, other dietary measures other than diet 
sodas could have been responsible for the perceived results of this study. With the vast 
number of products that contain APM these days and other ingredients present in APM 
products, it is difficult to isolate APM in human epidemiological studies. Combined with 
the challenge of controlling for confounding lifestyle variables, determining any adverse 
health effects in humans due to APM use is an uphill task. Future human studies that 
investigate the impact of APM on health should be designed in a way that participants 
only consume APM in its isolated form and have all other dietary and lifestyle factors 
controlled to the highest degree. Studies of this nature will give clearer insights to any 
health consequences related to APM use.  
Animal studies have given a clearer understanding between the relationship of 
APM use and metabolic disturbances. Rats that were administered very low doses of 
APM for eight weeks, 5-7 mg/kg body weight/day, were found to have increased blood 
glucose levels, compromised insulin function, and changes in gut microbiota (Palmnäs et 
al., 2014). The increase in blood propionate levels discovered in the APM-treated rats 
was believed to be the underlying cause of these changes in glucose levels and insulin 
function. Propionate is a SCFA that is produced by bacteria in the gut. Changes in the gut 
bacterial population were attributed to APM treatment and were what caused this 
elevation of propionate production. In addition to being a gluconeogenic agent and being 
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previously linked to insulin resistance, propionate has been associated with a number of 
other mechanisms and conditions such as changes in gene expression, autism, changes in 
mitochondrial function, and irritable bowel syndrome (Kimura et al., 2013; Larsson et al., 
2012; Frye et al., 2013; Lee & Tack, 2010). It is possible that sustained elevations in 
blood propionate levels as a result of long-term APM consumption could ultimately lead 
to the acquisition of any of these conditions or even other negative outcomes yet to be 
linked to increased propionate production. The APM dose administered to the rats was 
much lower than what is currently recommended by the FDA, 50 mg/kg body 
weight/day. The adverse health effects associated with this low dose over a short period 
of time raises the possibility that even low to moderate APM consumption can contribute 
to impairments in metabolic homeostatic mechanisms. Further studies looking at APM 
intake and its contribution to propionate production need to be conducted to confirm 
these findings.  
Research investigating the relationship between APM consumption and oxidative 
stress has shown that APM plays a role in the increased production of free radicals in the 
brain and RBCs and induction of apoptotic mechanisms in the brain (Ashok & 
Sheeladevi, 2014; Prokic et al., 2014). Methanol, one of the metabolites of APM, has 
been implicated in rises in the production of free radicals (Kadiiska & Mason, 2000). It is 
possible that increases in the activities of SOD, catalase, and glutathione peroxidase in 
the brain could have been in response to free radicals generated from the methanol 
exposure. In the study conducted by Ashok and Sheeladevi, plasma methanol 
concentrations in the APM-treated rats were found to be significantly higher than those in 
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the controls (p<0.05). Free radicals also play a role in the initiation of apoptotic processes 
(Raha & Robinson, 2001). The changes seen in the expressions of the Bcl-2, Bax, and 
caspase-3 genes by Ashok and Sheeladevi in the APM-treated rats could have been a 
secondary effect of APM exposure. When decreases in Bcl-2 expression and increases in 
Bax expression occur in neurons simultaneously, they give rise to apoptosis (Mbazima et 
al., 2008). Furthermore, increases in the expression of the pro-apoptotic Bax gene leads to 
mitochondrial release of cytochrome c, which also triggers apoptosis (Thomas et al., 
2000). Given the implications of oxidative stress in a wide number of diseases, these 
findings need to be investigated further in relation to their association with APM use. 
Further studies using larger sample sizes are required in order to confirm APM as the 
cause of the changes observed in oxidative stress and apoptotic markers. These studies 
should also look into whether APM gives rise to oxidative stress in any other organ 
systems.  
From a neurological perspective, the associations of APM to depression, 
irritability, and compromises in spatial orientation and memory raise even more questions 
on the safety of this artificial sweetener. In human subjects, these three symptoms were 
associated with APM when consumed for eight days at a dose of 25 mg/kg body 
weight/day, half the daily dose that the FDA currently recommends (Lindseth et al., 
2014). Even though APM intake was strictly regulated in this particular study and the 
subjects were both physically and mentally healthy prior, there are so many external 
variables that could have contributed to the results. However, the effect that APM has on 
the levels of monoamine neurotransmitters adds greater validity to these findings. Several 
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investigations of the effects of APM at the neurochemical level have shown APM to be 
associated with decreased levels of dopamine, serotonin, and noradrenaline in the brain 
(Abdel-Salam et al., 2012a, 2012b; Humphries et al., 2008). Depression has been linked 
to decreases in the levels of all three of these neurotransmitters (To et al., 2005). It is 
possible that the feelings of depression the subjects had after eight days of APM 
consumption were due to these changes. Decreases in dopamine have also been linked to 
impairments in working memory and the development of attention deficit hyperactivity 
disorder (Humphries et al., 2008).    
Decreases in serotonin levels can affect sleep cycles, appetite, temperature 
control, and moods. Serotonin also plays many important roles in brain development. It 
has been associated with the formation of synaptic circuits, the differentiation and 
maturation of neurons, and apoptotic mechanisms (Gaspar et al., 2003). Soffritti et al. 
showed that prenatal exposure to APM potentiated the already existing increased risk of 
cancer due to APM consumption (Soffritti et al., 2007). The consequences of decreased 
serotonin production present more cause for concern in pregnant women who consume 
this artificial sweetener. In regards to noradrenaline, decreased levels of this 
neurotransmitter have been associated with loss of attention and impulsiveness during 
child development (Humphries et al., 2008). It is possible for children who frequently 
consume APM to acquire these deficits over a period of time. Additionally, the down 
regulation of astrocyte GABA transporters that is a result of decreased serotonin can also 
have harmful effects during the developmental period. Throughout brain development, 
GABA plays an excitatory and trophic role and has been associated with the growth of 
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neurons and shaping of synapses (Owens & Kriegstein, 2002). Shifts in the levels of this 
neurotransmitter as a secondary consequence of APM consumption could potentially 
result in impairments in maturation of the brain. In order to confirm the changes APM 
brings about neurologically at the molecular level, further studies are required that 
investigate exactly to what extent APM metabolites rise in the blood, exactly what doses 
are responsible for those rises, and how drastically neurotransmitter levels change.  
In conclusion, numerous studies conducted on APM have shown that 
consumption of this artificial sweetener at both low and high doses contributes to the 
development of many diseases and conditions. These include lymphomas, leukemias, 
carcinomas, schwannomas, multiple myeloma, genotoxicity, diabetes, metabolic 
syndrome, oxidative stress, insulin resistance, premature apoptosis, and neurochemical 
imbalances. Although there are many other APM studies that say otherwise, there is 
enough research and evidence out there to show that there is a strong likelihood that 
APM is not completely safe. There is a vast amount of misleading information out there 
that can deceive people in regards to the safety of APM. For example, the Aspartame 
Information Center, an .org website which looks very credible, is ran by an organization 
that works directly with manufacturers and suppliers of low-calorie foods and beverages 
(Aspartame Information Center, 2015). People who have conflicts of interest present a 
great deal of this literature and information on APM that claims its safety. Because of 
this, future investigations that examine how the funding sources of studies and resources 
are related to reporting findings of APM safety are warranted, as they would shed more 
light on this controversial topic. As it stands, consumers of APM, whether it is at high or 
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low doses, may be at an increased risk of a variety of adverse health effects. The spread 
of this information to the public and reevaluation of the safety of APM are urgently 
needed.  
 
 
 
 
 
 
 
 
 
  
  
	  50 
REFERENCES 
 
Abdel-Salam, O. M. E., Salem, N. A., El-Shamarka, M. E. S., Hussein, J. S., Ahmed, N. 
a. S., & El-Nagar, M. E. S. (2012a). Studies on the effects of aspartame on memory and 
oxidative stress in brain of mice. European Review for Medical and Pharmacological 
Sciences, 16(15), 2092–2101. 	  
Abdel-Salam, O. M. E., Salem, N. A., & Hussein, J. S. (2012b). Effect of aspartame on 
oxidative stress and monoamine neurotransmitter levels in lipopolysaccharide-treated 
mice. Neurotoxicity Research, 21(3), 245–255. http://doi.org/10.1007/s12640-011-9264-9 	  
Alipour, A., van Oostrom, A. J. H. H. M., Izraeljan, A., Verseyden, C., Collins, J. M., 
Frayn, K. N., … Castro Cabezas, M. (2008). Leukocyte activation by triglyceride-rich 
lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(4), 792–797. 
http://doi.org/10.1161/ATVBAHA.107.159749 	  
Aruoma, D. O. I. (1998). Free radicals, oxidative stress, and antioxidants in human health 
and disease. Journal of the American Oil Chemists’ Society, 75(2), 199–212. 
http://doi.org/10.1007/s11746-998-0032-9 	  
Ashok, I., & Sheeladevi, R. (2014). Biochemical responses and mitochondrial mediated 
activation of apoptosis on long-term effect of aspartame in rat brain. Redox Biology, 2, 
820–831. http://doi.org/10.1016/j.redox.2014.04.011 	  
Aspartame. (2015). 
http://www.cancer.org/cancer/cancercauses/othercarcinogens/athome/aspartame 	  
Aspartame Information Center. (2015). Aspartame | Separating Fact From Fiction about 
Aspartame. Retrieved from http://www.aspartame.org/ 	  
Bártek, J., Bártková, J., Vojtĕsek, B., Stasková, Z., Lukás, J., Rejthar, A., … Lane, D. P. 
(1991). Aberrant expression of the p53 oncoprotein is a common feature of a wide 
spectrum of human malignancies. Oncogene, 6(9), 1699–1703. 	  
Beal, M. F., Hyman, B. T., & Koroshetz, W. (1993). Do defects in mitochondrial energy 
metabolism underlie the pathology of neurodegenerative diseases? Trends in 
Neurosciences, 16(4), 125–131. 	  
Bergendi, L., Benes, L., Duracková, Z., & Ferencik, M. (1999). Chemistry, physiology 
and pathology of free radicals. Life Sciences, 65(18-19), 1865–1874. 	  
	  51 
Borowski, T., Kokkinidis, L., Merali, Z., & Anisman, H. (1998). Lipopolysaccharide, 
central in vivo biogenic amine variations, and anhedonia. Neuroreport, 9(17), 3797–
3802. 	  
Campbell, M. H., Maynard, D., Roberti, J. W., & Emmanuel, M. K. (2012). A 
comparison of the psychometric strengths of the public-domain Zung Self-rating 
Depression Scale with the proprietary Beck Depression Inventory-II in Barbados. The 
West Indian Medical Journal, 61(5), 483–488. 	  
Castro, G. D., Costantini, M. H., Delgado de Layño, A. M. A., & Castro, J. A. (2002). 
Rat liver microsomal and nuclear activation of methanol to hydroxymethyl free radicals. 
Toxicology Letters, 129(3), 227–236. 	  
Chrostek, L., Jelski, W., Szmitkowski, M., & Puchalski, Z. (2003). Gender-related 
differences in hepatic activity of alcohol dehydrogenase isoenzymes and aldehyde 
dehydrogenase in humans. Journal of Clinical Laboratory Analysis, 17(3), 93–96. 
http://doi.org/10.1002/jcla.10076 	  
Dean, O., Bush, A. I., Berk, M., Copolov, D. L., & van den Buuse, M. (2009). 
Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in 
rats and mice. Behavioural Brain Research, 198(1), 258–262. 
http://doi.org/10.1016/j.bbr.2008.11.017 	  
FDA, C. for F. S. and A. (2007). Food Additives & Ingredients - FDA Statement on 
European Aspartame Study [WebContent]. 
http://www.fda.gov/Food/IngredientsPackagingLabeling/FoodAdditivesIngredients/ucm2
08580.htm 	  
Food and Drug Administration: Food Additive Approval Process Followed for 
Aspartame. (1987, June). http://www.gao.gov/products/HRD-87-46 	  
Formaldehyde and Cancer Risk. (2015). http://www.cancer.gov/cancertopics/causes-
prevention/risk-factors/cancer-causing-substances/formaldehyde/formaldehyde-fact-sheet 	  
Frye, R. E., Melnyk, S., & Macfabe, D. F. (2013). Unique acyl-carnitine profiles are 
potential biomarkers for acquired mitochondrial disease in autism spectrum disorder. 
Translational Psychiatry, 3, e220. http://doi.org/10.1038/tp.2012.143 	  
Gaspar, P., Cases, O., & Maroteaux, L. (2003). The developmental role of serotonin: 
news from mouse molecular genetics. Nature Reviews. Neuroscience, 4(12), 1002–1012. 
http://doi.org/10.1038/nrn1256 	  
Gold, M. D. (2002, January). Evidence File #7: Aspartame History. 
http://www.fda.gov/ohrms/dockets/dailys/03/Jan03/012203/02P-0317_emc-000202.txt 
	  52 
	  
Gombos, K., Varjas, T., Orsós, Z., Polyák, E., Peredi, J., Varga, Z., … Ember, I. (2007). 
The effect of aspartame administration on oncogene and suppressor gene expressions. In 
Vivo (Athens, Greece), 21(1), 89–92. 
 
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. 
A., … National Heart, Lung, and Blood Institute. (2005). Diagnosis and management of 
the metabolic syndrome: an American Heart Association/National Heart, Lung, and 
Blood Institute Scientific Statement. Circulation, 112(17), 2735–2752. 
http://doi.org/10.1161/CIRCULATIONAHA.105.169404 	  
Halliwell, B. (1992). Reactive oxygen species and the central nervous system. Journal of 
Neurochemistry, 59(5), 1609–1623. 	  
Humphries, P., Pretorius, E., & Naudé, H. (2008). Direct and indirect cellular effects of 
aspartame on the brain. European Journal of Clinical Nutrition, 62(4), 451–462. 
http://doi.org/10.1038/sj.ejcn.1602866 	  
Jr, L. J. F., & Stegink, L. D. (1988). Effect of Aspartame on Plasma Phenylalanine 
Concentration in Humans. In R. J. W. M.D & E. Ritter-Walker (Eds.), Dietary 
Phenylalanine and Brain Function (pp. 18–40). Birkhäuser Boston. Retrieved from 
http://link.springer.com/chapter/10.1007/978-1-4615-9821-3_3 	  
Kadiiska, M. B., & Mason, R. P. (2000). Acute methanol intoxication generates free 
radicals in rats: an ESR spin trapping investigation. Free Radical Biology & Medicine, 
28(7), 1106–1114. 	  
Kimura, I., Ozawa, K., Inoue, D., Imamura, T., Kimura, K., Maeda, T., … Tsujimoto, G. 
(2013). The gut microbiota suppresses insulin-mediated fat accumulation via the short-
chain fatty acid receptor GPR43. Nature Communications, 4, 1829. 
http://doi.org/10.1038/ncomms2852 	  
Koren, O., Goodrich, J. K., Cullender, T. C., Spor, A., Laitinen, K., Bäckhed, H. K., … 
Ley, R. E. (2012). Host remodeling of the gut microbiome and metabolic changes during 
pregnancy. Cell, 150(3), 470–480. http://doi.org/10.1016/j.cell.2012.07.008 	  
Kummer, U., Zobeley, J., Brasen, J. C., Fahmy, R., Kindzelskii, A. L., Petty, A. R., … 
Petty, H. R. (2007). Elevated glucose concentrations promote receptor-independent 
activation of adherent human neutrophils: an experimental and computational approach. 
Biophysical Journal, 92(7), 2597–2607. http://doi.org/10.1529/biophysj.106.086769 	  
 
 
	  53 
Larsson, E., Tremaroli, V., Lee, Y. S., Koren, O., Nookaew, I., Fricker, A., … Bäckhed, 
F. (2012). Analysis of gut microbial regulation of host gene expression along the length 
of the gut and regulation of gut microbial ecology through MyD88. Gut, 61(8), 1124–
1131. http://doi.org/10.1136/gutjnl-2011-301104 	  
Lee, K. J., & Tack, J. (2010). Altered intestinal microbiota in irritable bowel syndrome. 
Neurogastroenterology and Motility: The Official Journal of the European 
Gastrointestinal Motility Society, 22(5), 493–498. 	  
Levi, J., Segal, L., St. Laurent, R., Lang, A., & Rayburn, J. (2012, September). F as in 
Fat: How Obesity Threatens America’s Future 2012. 
http://www.rwjf.org/en/library/research/2012/09/f-as-in-fat--how-obesity-threatens-
america-s-future-2012.html 	  
Lim, U., Subar, A. F., Mouw, T., Hartge, P., Morton, L. M., Stolzenberg-Solomon, R., … 
Schatzkin, A. (2006). Consumption of aspartame-containing beverages and incidence of 
hematopoietic and brain malignancies. Cancer Epidemiology, Biomarkers & Prevention: 
A Publication of the American Association for Cancer Research, Cosponsored by the 
American Society of Preventive Oncology, 15(9), 1654–1659. 
http://doi.org/10.1158/1055-9965.EPI-06-0203 	  
Lindseth, G. N., Coolahan, S. E., Petros, T. V., & Lindseth, P. D. (2014). 
Neurobehavioral effects of aspartame consumption. Research in Nursing & Health, 
37(3), 185–193. http://doi.org/10.1002/nur.21595 	  
Lynch, R. E., & Fridovich, I. (1978). Permeation of the erythrocyte stroma by superoxide 
radical. The Journal of Biological Chemistry, 253(13), 4697–4699. 	  
Magnuson, B. A., Burdock, G. A., Doull, J., Kroes, R. M., Marsh, G. M., Pariza, M. W., 
… Williams, G. M. (2007). Aspartame: a safety evaluation based on current use levels, 
regulations, and toxicological and epidemiological studies. Critical Reviews in 
Toxicology, 37(8), 629–727. http://doi.org/10.1080/10408440701516184 	  
Magnuson, B., & Williams, G. M. (2008). Carcinogenicity of aspartame in rats not 
proven. Environmental Health Perspectives, 116(6), A239–240; author reply A240. 
http://doi.org/10.1289/ehp.10881 	  
Mbazima, V. G., Mokgotho, M. P., February, F., Rees, D. J. G., & Mampuru, L. J. M. 
(2008). Alteration of Bax-to-Bcl-2 ratio modulates the anticancer activity of methanolic 
extract of Commelina benghalensis (Commelinaceae) in Jurkat T cells. African Journal 
of Biotechnology, 7(20). http://doi.org/10.4314/ajb.v7i20.59373 	  
 
	  54 
Mori, K., Kaneko, Y. S., Nakashima, A., Fujiwara, K., Nagatsu, I., & Ota, A. (2003). 
Effect of peripheral lipopolysaccharide injection on dopamine content in murine anterior 
olfactory nucleus. Journal of Neural Transmission (Vienna, Austria: 1996), 110(1), 31–
50. http://doi.org/10.1007/s00702-002-0771-y 	  
Nettleton, J. A., Lutsey, P. L., Wang, Y., Lima, J. A., Michos, E. D., & Jacobs, D. R. 
(2009). Diet Soda Intake and Risk of Incident Metabolic Syndrome and Type 2 Diabetes 
in the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care, 32(4), 688–694. 
http://doi.org/10.2337/dc08-1799 	  
Ota, A., Kaneko, Y. S., Mori, K., Nakashima, A., Nagatsu, I., & Nagatsu, T. (2007). 
Effect of peripherally administered lipopolysaccharide (LPS) on GTP cyclohydrolase I, 
tetrahydrobiopterin and norepinephrine in the locus coeruleus in mice. Stress 
(Amsterdam, Netherlands), 10(2), 131–136. http://doi.org/10.1080/10253890701350511 	  
Owens, D. F., & Kriegstein, A. R. (2002). Is there more to GABA than synaptic 
inhibition? Nature Reviews. Neuroscience, 3(9), 715–727. http://doi.org/10.1038/nrn919 	  
Palmnäs, M. S. A., Cowan, T. E., Bomhof, M. R., Su, J., Reimer, R. A., Vogel, H. J., … 
Shearer, J. (2014). Low-dose aspartame consumption differentially affects gut 
microbiota-host metabolic interactions in the diet-induced obese rat. PloS One, 9(10), 
e109841. http://doi.org/10.1371/journal.pone.0109841 	  
Pankow, D., & Jagielki, S. (1993). Effect of methanol or modifications of the hepatic 
glutathione concentration on the metabolism of dichloromethane to carbon monoxide in 
rats. Human & Experimental Toxicology, 12(3), 227–231. 	  
Patsoukis, N., Zervoudakis, G., Panagopoulos, N. T., Georgiou, C. D., Angelatou, F., & 
Matsokis, N. A. (2004). Thiol redox state (TRS) and oxidative stress in the mouse 
hippocampus after pentylenetetrazol-induced epileptic seizure. Neuroscience Letters, 
357(2), 83–86. http://doi.org/10.1016/j.neulet.2003.10.080 	  
Petnehazy, T., Stokes, K. Y., Wood, K. C., Russell, J., & Granger, D. N. (2006). Role of 
blood cell-associated AT1 receptors in the microvascular responses to 
hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(2), 313–
318. http://doi.org/10.1161/01.ATV.0000193625.32499.71 	  
Prokic, M. D., Paunovic, M. G., Matic, M. M., Djordjevic, N. Z., Ognjanovic, B. I., Stajn, 
A. S., & Saicic, Z. S. (2014). Prooxidative effects of aspartame on antioxidant defense 
status in erythrocytes of rats. Journal of Biosciences, 39(5), 859–866. 	  
Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J.-S., … Crews, F. T. 
(2007). Systemic LPS causes chronic neuroinflammation and progressive 
neurodegeneration. Glia, 55(5), 453–462. http://doi.org/10.1002/glia.20467 
	  55 
	  
Raha, S., & Robinson, B. H. (2001). Mitochondria, oxygen free radicals, and apoptosis. 
American Journal of Medical Genetics, 106(1), 62–70. http://doi.org/10.1002/ajmg.1398 	  
Saccharin. (2015). Saccharin, a sugar substitute for more than 100 years. Retrieved from 
http://saccharin.org/ 	  
Sakamoto, S., Kambara, M., & Tanno, Y. (2001). Response styles and cognitive and 
affective symptoms of depression. Personality and Individual Differences, 31(7), 1053–
1065. http://doi.org/10.1016/S0191-8869(00)00203-8 
 
Schernhammer, E. S., Bertrand, K. A., Birmann, B. M., Sampson, L., Willett, W. C., & 
Feskanich, D. (2012). Consumption of artificial sweetener- and sugar-containing soda 
and risk of lymphoma and leukemia in men and women. The American Journal of 
Clinical Nutrition, 96(6), 1419–1428. http://doi.org/10.3945/ajcn.111.030833 	  
Soffritti, M., Belpoggi, F., Esposti, D. D., Lambertini, L., Tibaldi, E., & Rigano, A. 
(2006). First Experimental Demonstration of the Multipotential Carcinogenic Effects of 
Aspartame Administered in the Feed to Sprague-Dawley Rats. Environmental Health 
Perspectives, 114(3), 379–385. http://doi.org/10.1289/ehp.8711 	  
Soffritti, M., Belpoggi, F., Tibaldi, E., Esposti, D. D., & Lauriola, M. (2007). Life-span 
exposure to low doses of aspartame beginning during prenatal life increases cancer 
effects in rats. Environmental Health Perspectives, 115(9), 1293–1297. 
http://doi.org/10.1289/ehp.10271 	  
Soffritti, M., Padovani, M., Tibaldi, E., Falcioni, L., Manservisi, F., & Belpoggi, F. 
(2014). The carcinogenic effects of aspartame: The urgent need for regulatory re-
evaluation. American Journal of Industrial Medicine, 57(4), 383–397. 
http://doi.org/10.1002/ajim.22296 	  
Stegink, L. D. (1987). The aspartame story: a model for the clinical testing of a food 
additive. The American Journal of Clinical Nutrition, 46(1 Suppl), 204–215. 	  
Thomas, A., Giesler, T., & White, E. (2000). p53 mediates bcl-2 phosphorylation and 
apoptosis via activation of the Cdc42/JNK1 pathway. Oncogene, 19(46), 5259–5269. 
http://doi.org/10.1038/sj.onc.1203895 	  
To, S. E., Zepf, R. A., & Woods, A. G. (2005). The symptoms, neurobiology, and current 
pharmacological treatment of depression. The Journal of Neuroscience Nursing: Journal 
of the American Association of Neuroscience Nurses, 37(2), 102–107. 	  
Tremaroli, V., & Bäckhed, F. (2012). Functional interactions between the gut microbiota 
and host metabolism. Nature, 489(7415), 242–249. http://doi.org/10.1038/nature11552 
	  56 
Vandenberg, S. G., & Kuse, A. R. (1978). Mental rotations, a group test of three-
dimensional spatial visualization. Perceptual and Motor Skills, 47(2), 599–604. 
http://doi.org/10.2466/pms.1978.47.2.599 	  
Walton, R. G. (n.d.). Survey of Aspartame Studies: Correlation of Outcome & Funding 
Sources. Retrieved from http://dorway.com/aspartame-the-bad-news-repost/peer-
reviewed-aspartame-studies/ 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  57 
CURRICULUM VITAE 
 
 
Naveed Majd 
24235 Park Granada •  Calabasas, CA 91302 • (818) 448-8216 • 
naveed.majd@gmail.com • 1989 
 
 
EDUCATION 
 
Boston University                                                                                     Fall 2013-Present                                                                      
School of Medicine 
Master of Science Candidate, Medical Sciences  
 
University of California, Los Angeles                                         Fall 2007-Summer 2011 
College of Letters and Sciences 
Bachelor of Science, Physiological Science  
 
 
WORK EXPERIENCE  
Ronald Reagan UCLA Medical Center, Los Angeles, CA 
Emergency Trauma Technician          October 2011-June 2012 
• Supported nurses and physicians in the Emergency Department. 
• Performed a wide range of patient care skills, monitored EKGs, and transported 
patients. 
UCLA Emergency Medical Services, Los Angeles, CA 
Emergency Medical Technician                                                     June 2009-October 2011                                                                                      
• Responded to 911 calls at UCLA and the surrounding Westwood area.          
• Staffed special events on campus and coordinated the campus lost and found.   
Field Training Officer                                               July 2010-October 2011       
• Taught trainees medical and equipment guidelines, as well as EMS procedures. 
• Directed practice and testing simulation sessions. 
Maintenance Coordinator                                                                   April 2010-June 2010                                   
• Maintained proper functioning of ambulances and medical equipment. 
• Managed and organized all medical supplies. 
Team Representative                       January 2010-March 2010 
• Continually gathered ideas and opinions of colleagues.  
• Spoke on behalf of employees at monthly meetings.    
 
 
 
	  58 
INVOLVEMENT 
 
UC Irvine Medical Center Volunteer     October 2014-Present 
• Assist with the patient discharges, specimen transports, and patient deliveries. 
• Carry out various administrative tasks in the medical center and medical offices. 
American Heart Association (AHA) Volunteer       November 2012-July 2013 
• Assist with community events and activities in the Greater Los Angeles area. 
• Involved in various AHA programs and CPR education. 
Research with Dr. Baxter Larmon, PhD, MICP            January 2011-December 2011 
• Gathered 911 call data in the Los Angeles area to assess CPR administration.  
• Analyzed effectiveness of CPR in various gurney positions. 
Volunteer at the David Geffen School of Medicine at UCLA            Summer/Fall 2010 
• Taught physical exam skills to 1st year medical students. 
• Instructed airway management skills and techniques to 3rd year medical students.  
 
 
HONORS 
• Emergency Medical Technician of the Quarter                                                                   
Spring 2011 
• Alpha Lambda Delta & Phi Eta Sigma Academic National Honor Societies Inductee      
Spring 2008 
  
 
 
LANGUAGES 
 
• English (Fluent) 
• Farsi  (Fluent) 
• Spanish (Advanced Conversational) 
 
